Retinitis pigmentosa is one of the commonest forms of inherited retina degenerative blindness worldwide. With the advent of molecular technologies it has become easier to identify the genetic defects ...

Steven Pittler, Ph.D., at the University of Alabama at Birmingham has sought to find modifier genes for the hereditary eye disorder retinitis pigmentosa type 59. After onset in one’s late teens, RP59 ...

Retinitis pigmentosa is characterised by changes in the pigment layer of the retina. The pigment layer of the retina invades and damages the nerve layer and with time it affects the blood vessels of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation for chemically induced photoreceptor-like cells to treat retinitis ...

Applied Genetic Technologies (NASDAQ:AGTC-1%) files an Investigational New Drug (IND) application with the FDA seeking approval to launch a Phase 1/2 clinical trial assessing its RPGR gene therapy ...

PYC Therapeutics raised AU$40 million of an anticipated AU$74 million (US$48.6 million) capital raise to advance three candidates, including lead candidate VP-001, which could potentially be the first ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has announced positive results from its ongoing clinical trials for VP-001, a treatment for the childhood blinding disease ...

Retinitis pigmentosa is a Mendelian disease with a very elevated genetic heterogeneity. Most mutations are responsible for less than 1% of cases, making molecular diagnosis a multigene screening ...

Figure 1: Rod cell rescue in diltiazem-treated rd mice. Figure 3: Diltiazem-induced photoreceptor rescue in retinal sections of rd mice. Figure 5: ERGs after diltiazem treatment in rd mice and ...